United Therapeutics (UTHR) Stock Highlights

358.93 | -2.04%

2025-01-21 00:50:44

United Therapeutics specializes in drug development for pulmonary arterial hypertension, a rare and progressive disease marked by abnormally high blood pressure in the arteries of the lungs. The companys therapies for PAH largely focus on the prostacyclin pathway, and many of its treatments are based on the same molecule, treprostinil. Most of the companys sales are generated within the United States. United Therapeutics also markets a pediatric oncology drug, but its focus largely remains in pulmonary arterial hypertension.

Statistics

Range Today

357.25 372.34

Volume Today 248.3K

Range 1 Year

208.62 417.82

Volume 1 Year 110.84M

Range 3 Year

158.38 417.82

Volume 3 Year 315.72M

Range 10 Year

74.31 417.82

Volume 10 Year 1.22B

Highlights

Market Capitalization 16.02B (large)

Floating Shares 40.93M

Current Price 358.93

Price To Earnings 16.37

Price To Revenue 4.87

Price To Book 2.62

Earnings Per Share 22.75

Payout Ratio 0%

Performance

Latest -2.04%

1 Month -3.56%

3 Months -2.99%

6 Months +9.22%

1 Year +64.77%

3 Years +67.81%

5 Years +279.9%

10 Years +153.16%

Benchmarks

Market Capitalization

17 / 368

Gross Profits

6 / 278

Total Revenue

10 / 300

Total Rank

3 / 368

Free Cashflow

5 / 352

Performance 5 years

24 / 368

Obligatory risk notice

We would like to point out that the contents of this website are for general information purposes only and do not constitute recommendations for the purchase or sale of specific financial instruments, and therefore do not constitute investment advice. In particular, marketstorylabs.com and its creators cannot assess the extent to which information / recommendations made on the pages correspond to your investment objectives, your risk tolerance and your ability to bear losses. Therefore, if you make any investment decisions based on information on the site, you do so solely on your own responsibility and at your own risk. This in turn means that neither marketstorylabs.com nor its creators are liable for any losses incurred as a result of investment decisions based on the information on the marketstorylabs.com website or other media used.